PLYX · Polaryx Therapeutics Inc. Common Stock
View on chartInsiders & Stakes
| Alex Keun Mo Yang Chief Executive Officer | ▲ Buy | Open Market | 24,233,249 Shares held | 5/27/2026 | View profile |
| G. Michael Landis Chief Financial Officer | ▲ Buy | Open Market | 228,225 Shares held | 2/18/2026 | View profile |
Transaction History
| Alex Keun Mo Yang | ▲ Buy | Open Market | 88,453 | $360K | 5/27/2026 |
| G. Michael Landis | ▲ Buy | Open Market | 2,867 | $8K | 2/18/2026 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
PLYX Included in List of 20 Premarket Movers
Polaryx Therapeutics (PLYX) was featured in a Benzinga report listing 20 stocks moving in premarket trading. The article highlights Webuy Global as a primary driver of market movement, with PLYX included in the broader list of active tickers. No specific reasons for PLYX's price action were detailed in the provided summary. The stock currently trades near its 52-week low, with technical indicators showing a support rejection at $2.06.
PLYX Included in List of 20 Premarket Movers. Polaryx Therapeutics (PLYX) was featured in a Benzinga report listing 20 stocks moving in premarket trading. The article highlights Webuy Global as a primary driver of market movement, with PLYX included in the broader list of active tickers. No specific reasons for PLYX's price action were detailed in the provided summary. The stock currently trades near its 52-week low, with technical indicators showing a support rejection at $2.06.